Yan L, Chen L, Qian K, et al. - Researchers undertook this retrospective analysis to assess the safety as well as the efficacy of transarterial chemoembolization (TACE) and iodine 125 seeds implantation (ISI) for unresectable or “ablation unsuitable” hepatocellular carcinoma (HCC) in the caudate lobe (CL) identified at the initial presentation in clinical practice. Participants were 20 HCC-CL patients receiving sequential TACE and ISI from January 2014 to October 2018. A technical success rate of 100% was achieved, as all the patients received 28 ISI treatments. A median overall survival (OS) of 35 months was reported. The 1-, 3-, and 5-year OS rates were estimated to be 100%, 63.2%, and 11.1%, respectively. A median progression-free survival of 16 months and objective response rate of 60.0% was obtained. In multivariable analysis, two significant factors related to OS were: Barcelona Clinic Liver Cancer stage B and tumor size > 3 cm. Findings revealed that survival benefits were conferred by sequential TACE and ISI in patients with HCC-CL and it deserves consideration as a dependable therapy for surgeons and interventional radiologists.